Demand for access to innovative medicines can start building well before drug approval and may continue right through to discontinuation of a product line.
So enabling and maintaining access for patients indeed should be a strategic imperative from top management down. Companies should start thinking about Managed Access Programmes (MAPs) as early as possible in the transition from drug development to commercialisation.
Idis, a global leader in MAPs, looks at the best strategies for optimising the product experience and value on all sides.
